APLS Apellis Pharmaceuticals, Inc.

NEUTRAL Impact: 2/10 25-NSE
Horizon immediate Filed May 14, 2026 Processed 1mo ago SEC 0001354457-26-000449
Notable filing: 25-NSE
Latest settled — T+1d ⚠ clustered
APLS ▲ 0.00% at T+1d
NEUTRAL call ✗ call lost 0.00% · α vs SPY +1.23% · entry $41.03 → $41.03
Next anchor: T+5d due 25d ago
Entry anchored
May 13, 03:59 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +1.23%
$41.03
settled 4w ago
T+5d
call — · α —
due 25d ago
T+20d
call — · α —
due 3d ago
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May 14, 2026, following the completion of Biogen's acquisition. The delisting is a procedural step after the merger closed, with APLS stockholders receiving $41.00 per share plus CVRs.

Actionable Insight

The delisting is a routine administrative step following the completed acquisition. No further trading action is possible in APLS common stock. Monitor CVR milestone payments tied to SYFOVRE sales targets for potential value realization.

Key Facts

  • Form 25-NSE filed by Nasdaq Stock Market LLC to delist Apellis common stock under Rule 12d2-2(a)(3).
  • Effectiveness date is May 14, 2026, the same day as the filing.
  • Delisting follows Biogen's completed acquisition of Apellis for $41.00 per share plus CVRs.
  • The security is removed from listing and registration due to the merger, not due to any operational failure.

Financial Impact

No new financial impact; delisting is a procedural step after the $5.3B acquisition closed at $41.00/share plus CVRs.

Risk Factors

  • CVR milestone payments may not be achieved if SYFOVRE sales targets are missed.
  • No further liquidity in APLS common stock post-delisting.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
30% bullish (27 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000449
Document: 0001354457-26-000449-index-headers.html0001354457-26-000449
Document: 0001354457-26-000449-index.html0001354457-26-000449
Document: 0001354457-26-000449.txt0001354457-26-000449
5 reports for APLS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for APLS — sortable, filterable
Type Now
May 26, 2026
19d ago
15-12G
NEUTRAL ★ 6/10
awaiting T+1
May 14, 2026
4w ago
25-NSE
NEUTRAL ★ 2/10
$41.03 $41.03· 0.00%▲ +1.23%
May 14, 2026
4w ago
8-K
BULLISH ★ 8/10
$41.03 $41.03· 0.00%▲ +1.23%
May 4, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$40.97 $40.97· 0.00%▼ −0.80%
Mar 27, 2026
11w ago
Institutional Cluster
MIXED ★ 6/10
$16.97 $17.09▲ +0.71%▲ +1.06%
Showing 5 of 5

US Market Status

Market Closed — Opens in 4h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access